NASDAQ:PODD Insulet (PODD) Stock Price, News & Analysis $214.75 -1.36 (-0.63%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$211.27â–Ľ$217.7250-Day Range$180.69â–Ľ$216.1152-Week Range$125.82â–Ľ$223.56Volume559,605 shsAverage Volume835,722 shsMarket Capitalization$15.04 billionP/E Ratio65.08Dividend YieldN/APrice Target$225.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Insulet alerts: Email Address Insulet MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside4.9% Upside$225.29 Price TargetShort InterestHealthy4.04% of Shares Sold ShortDividend StrengthN/ASustainability-1.20Upright™ Environmental ScoreNews Sentiment0.76Based on 8 Articles This WeekInsider TradingSelling Shares$2.04 M Sold Last QuarterProj. Earnings Growth26.32%From $3.04 to $3.84 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.46 out of 5 starsMedical Sector97th out of 910 stocksSurgical & Medical Instruments Industry14th out of 95 stocks 2.4 Analyst's Opinion Consensus RatingInsulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageInsulet has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insulet's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.04% of the outstanding shares of Insulet have been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently increased by 4.43%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsulet has received a 80.74% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Insulin pumps" product. See details.Environmental SustainabilityThe Environmental Impact score for Insulet is -1.20. Previous Next 3.2 News and Social Media Coverage News SentimentInsulet has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Insulet this week, compared to 9 articles on an average week.Search Interest9 people have searched for PODD on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat Follows7 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,039,316.00 in company stock.Percentage Held by InsidersOnly 0.47% of the stock of Insulet is held by insiders.Read more about Insulet's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Insulet are expected to grow by 26.32% in the coming year, from $3.04 to $3.84 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 65.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 65.08, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.64.Price to Earnings Growth RatioInsulet has a PEG Ratio of 3.79. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioInsulet has a P/B Ratio of 20.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Insulet's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Insulet Stock (NASDAQ:PODD)Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.Read More PODD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PODD Stock News HeadlinesSeptember 7 at 2:12 AM | finance.yahoo.comInsulet’s (PODD) Sales And Margins Surpassed ExpectationsSeptember 5 at 11:43 AM | markets.businessinsider.comStrong Growth and Market Leadership Support Buy Rating for InsuletSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.September 5 at 10:01 AM | seekingalpha.comInsulet: Turning More Constructive, Valuations Still StretchedSeptember 4 at 7:02 PM | investors.comStock Market Cools, But S&P 500 Finds Support At This Key Level; Insulet Breaks Out (Live Coverage)September 4 at 1:23 PM | benzinga.comInsider Selling: Prem Singh Unloads $368K Of Insulet StockAugust 31, 2024 | finance.yahoo.comHere's Why We Think Insulet (NASDAQ:PODD) Is Well Worth WatchingAugust 31, 2024 | forbes.comWhat Helped Insulet Stock Gain 10% This Week?September 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 30, 2024 | fool.comWhy Insulet Stock Was Zooming Higher This WeekAugust 28, 2024 | markets.businessinsider.comInsulet Stock Buy Rating: FDA Approval Expands Market Reach for Omnipod 5August 28, 2024 | benzinga.comHere's How Much You Would Have Made Owning Insulet Stock In The Last 10 YearsAugust 28, 2024 | marketwatch.comInsulet Shares Rise as FDA Clears Omnipod 5 for Type 2 Diabetes PatientsAugust 28, 2024 | markets.businessinsider.comInsulet’s Omnipod 5 Expansion into Type 2 Diabetes Market: A Strong Buy RatingAugust 28, 2024 | markets.businessinsider.comInsulet's Omnipod 5 Automated Insulin Delivery System Receives FDA Clearance For Type 2 DiabetesAugust 27, 2024 | investopedia.comS&P 500 Gains and Losses Today: Medical Device Makers ResMed, Insulet Lead IndexAugust 27, 2024 | markets.businessinsider.comFDA Clears Insulet's Omnipod 5 Automated Insulin Delivery System For People With Type 2 DiabetesAugust 26, 2024 | sg.finance.yahoo.comOmnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 DiabetesSee More Headlines Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:PODD CUSIP45784P10 CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees3,000Year Founded2000Price Target and Rating Average Stock Price Target$225.29 High Stock Price Target$260.00 Low Stock Price Target$184.00 Potential Upside/Downside+4.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$3.30 Trailing P/E Ratio65.08 Forward P/E Ratio70.64 P/E Growth3.79Net Income$206.30 million Net Margins21.11% Pretax Margin14.28% Return on Equity30.73% Return on Assets9.10% Debt Debt-to-Equity Ratio1.36 Current Ratio3.60 Quick Ratio2.71 Sales & Book Value Annual Sales$1.87 billion Price / Sales8.03 Cash Flow$4.02 per share Price / Cash Flow53.43 Book Value$10.49 per share Price / Book20.47Miscellaneous Outstanding Shares70,040,000Free Float69,711,000Market Cap$15.04 billion OptionableOptionable Beta1.21 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. James R. Hollingshead Ph.D. (Age 61)President, CEO & Director Comp: $2.88MMs. Lauren Budden (Age 49)Group VP, Chief Accounting Officer & Controller Comp: $794.05kMr. Mark Field (Age 53)Senior VP & CTO Comp: $954.14kMr. John Wodick Kapples (Age 64)Senior VP & General Counsel Comp: $1.02MMs. Shacey Petrovic (Age 51)Director & Advisor Comp: $28.57kMr. Eric Benjamin (Age 41)Executive VP, Chief Product & Customer Experience Officer Comp: $1.14MMs. Ana Maria Chadwick (Age 52)Executive VP, CFO & Treasurer Mr. Prem Singh (Age 47)Senior Vice President of Global Operations Ms. Deborah R. Gordon CPA (Age 53)Vice President of Investor Relations Ms. Laetitia Cousin (Age 48)Senior VP of Regulatory Affairs, Quality Assurance & Compliance More ExecutivesKey CompetitorsAbiomedNASDAQ:ABMDiRhythm TechnologiesNASDAQ:IRTCNovoCureNASDAQ:NVCREdwards LifesciencesNYSE:EWIDEXX LaboratoriesNASDAQ:IDXXView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 4,114 shares on 9/5/2024Ownership: 0.006%Clearbridge Investments LLCBought 75,526 shares on 8/27/2024Ownership: 1.913%Teachers Retirement System of The State of KentuckySold 170 shares on 8/26/2024Ownership: 0.050%Founders Financial Alliance LLCBought 1,011 shares on 8/26/2024Ownership: 0.001%Truist Financial CorpSold 454 shares on 8/21/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions PODD Stock Analysis - Frequently Asked Questions How have PODD shares performed this year? Insulet's stock was trading at $216.98 on January 1st, 2024. Since then, PODD stock has decreased by 1.0% and is now trading at $214.75. View the best growth stocks for 2024 here. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) announced its quarterly earnings data on Thursday, August, 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing analysts' consensus estimates of $0.56 by $0.01. The firm's revenue for the quarter was up 23.2% compared to the same quarter last year. What is Shacey Petrovic's approval rating as Insulet's CEO? 61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are Insulet's major shareholders? Insulet's top institutional investors include Baillie Gifford & Co. (2.69%), Clearbridge Investments LLC (1.91%), William Blair Investment Management LLC (1.35%) and American Century Companies Inc. (1.26%). Insiders that own company stock include Charles Alpuche, Timothy J Scannell, James Hollingshead, Wayde D Mcmillan, Bret Christensen, Mark N Field, Michael P Spears, Dan Manea, Prem Singh, Shacey Petrovic and Luciana Borio. View institutional ownership trends. How do I buy shares of Insulet? Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some other companies that Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ) and Walt Disney (DIS). This page (NASDAQ:PODD) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PODD Stock Alerts